Sacubitril/Valsartan Versus Valsartan in Heart Failure

• Status: Recruiting
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study was to identify potential prognostic factors of sacubitril/valsartan vs Valsartan treatment response.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Collaborator: Tanta University
• Treatments: Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• Patients with HF were enrolled if aged > 35 years,

• Stable symptomatic systolic chronic HF (≥ 4 weeks), with left ventricular ejection fraction (LVEF) < 35%,

• NYHA class II-III,

• Sinus rhythm and resting HR ≥ 70 beats/min on optimised standard medical therapy.

Exclusion Criteria:

• Patients with acute decompensation,

• Cerebrovascular events during the previous 6 months,

• Pregnancy, breastfeeding,

• Any valve dysfunction/abnormality,

• Active myocarditis,

• Second-degree and third-degree atrioventricular block,

• Sick sinus syndrome.